|
1
|
Selvetella G, Notte A, Maffei A, Calistri
V, Scamardella V, Frati G, Trimarco B, Colonnese C and Lembo G:
Left ventricular hypertrophy is associated with asymptomatic
cerebral damage in hypertensive patients. Stroke. 34:1766–1770.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Turer AT and Hill JA: Pathogenesis of
myocardial ischemia-reper-fusion injury and rationale for therapy.
Am J Cardiol. 106:360–368. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Eltzschig HK and Eckle T: Ischemia and
reperfusion-from mechanism to translation. Nat Med. 17:1391–1401.
2011. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Mohammadi MT and Dehghani GA: Acute
hypertension induces brain injury and blood-brain barrier
disruption through reduction of claudins mRNA expression in rat.
Pathol Res Pract. 210:985–990. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Corona JC and Duchen MR: PPARgamma as a
therapeutic target to rescue mitochondrial function in neurological
disease. Free Radic Biol Med. 100:153–163. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kvandova M, Majzunova M and Dovinova I:
The role of PPARgamma in cardiovascular diseases. Physiol Res.
65:S343–S363. 2016.PubMed/NCBI
|
|
7
|
Chaudhry A, Carthan KA, Kang BY, Calvert
J, Sutliff RL and Michael Hart C: PPARgamma attenuates
hypoxia-induced hypertrophic transcriptional pathways in the heart.
Pulm Circ. 7:98–107. 2017. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lan LF, Zheng L, Yang X, Ji XT, Fan YH and
Zeng JS: Peroxisome proliferator-activated receptor-gamma agonist
pioglitazone ameliorates white matter lesion and cognitive
impairment in hypertensive rats. CNS Neurosci Ther. 21:410–416.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Afzal S, Sattar MA, Johns EJ, Abdulla MH,
Akhtar S, Hashmi F and Abdullah NA: Interaction between irbesartan,
peroxisome proliferator-activated receptor (PPAR-gamma), and
adiponectin in the regulation of blood pressure and renal function
in spontaneously hypertensive rats. J Physiol Biochem. 72:593–604.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Maccallini C, Mollica A and Amoroso R: The
positive regulation of eNOS signaling by PPAR agonists in
cardiovascular diseases. Am J Cardiovasc Drugs. 17:273–281. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Li Y, Liu J, Gao D, Wei J, Yuan H, Niu X
and Zhang Q: Age-related changes in hypertensive brain damage in
the hippocampi of spontaneously hypertensive rats. Mol Med Rep.
13:2552–2560. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2−ΔΔCt method. Methods. 25:402–408. 2001. View Article : Google Scholar
|
|
13
|
Imig JD, Walsh KA, Hye Khan MA, Nagasawa
T, Cherian-Shaw M, Shaw SM and Hammock BD: Soluble epoxide
hydrolase inhibition and peroxisome proliferator activated receptor
gamma agonist improve vascular function and decrease renal injury
in hypertensive obese rats. Exp Biol Med (Maywood). 237:1402–1412.
2012. View Article : Google Scholar
|
|
14
|
Kadiiska MB, Bonini MG, Ruggiero C,
Cleland E, Wicks S and Stadler K: Thiazolidinedione treatment
decreases oxidative stress in spontaneously hypertensive heart
failure rats through attenuation of inducible nitric oxide
synthase-mediated lipid radical formation. Diabetes. 61:586–596.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Paravicini TM and Touyz RM: Redox
signaling in hypertension. Cardiovasc Res. 71:247–258. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Patel M, Li QY, Chang LY, Crapo J and
Liang LP: Activation of NADPH oxidase and extracellular superoxide
production in seizure-induced hippocampal damage. J Neurochem.
92:123–131. 2005. View Article : Google Scholar
|
|
17
|
Jiang T, Gao L, Shi J, Lu J, Wang Y and
Zhang Y: Angiotensin-(1-7) modulates renin-angiotensin system
associated with reducing oxidative stress and attenuating neuronal
apoptosis in the brain of hypertensive rats. Pharmacol Res.
67:84–93. 2013. View Article : Google Scholar
|
|
18
|
Ramalingam M and Kim SJ: Reactive
oxygen/nitrogen species and their functional correlations in
neurodegenerative diseases. J Neural Transm (Vienna). 119:891–910.
2012. View Article : Google Scholar
|
|
19
|
Charriaut-Marlangue C and Ben-Ari Y: A
cautionary note on the use of the TUNEL stain to determine
apoptosis. Neuroreport. 7:61–64. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Napoleone P, Ferrante F, Ghirardi O,
Ramacci MT and Amenta F: Age-dependent nerve cell loss in the brain
of Sprague-Dawley rats: Effect of long term acetyl-L-carnitine
treatment. Arch Gerontol Geriatr. 10:173–185. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Beach TG, Walker R and McGeer EG: Patterns
of gliosis in Alzheimer's disease and aging cerebrum. Glia.
2:420–436. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kvandová M, Majzúnová M and Dovinová I:
The role of PPARgamma in cardiovascular diseases. Physiol Res.
65:S343–S363. 2016.PubMed/NCBI
|
|
23
|
Li WL, Liang X, Wang X, Zhang XD, Liu R,
Zhang W, Chen HL, Qin XJ, Bai H and Hai CX: Protective effect of
the peroxisome proliferator-activated receptor (PPAR)-gamma, ligand
rosiglitazone on tertbutyl hydroperoxide-induced QZG cell injury.
Exp Toxicol Pathol. 63:527–533. 2011. View Article : Google Scholar
|
|
24
|
Raji A, Seely EW, Bekins SA, Williams GH
and Simonson DC: Rosiglitazone improves insulin sensitivity and
lowers blood pressure in hypertensive patients. Diabetes Care.
26:172–178. 2003. View Article : Google Scholar
|
|
25
|
Dobrian AD, Schriver SD, Khraibi AA and
Prewitt RL: Pioglitazone prevents hypertension and reduces
oxidative stress in diet-induced obesity. Hypertension. 43:48–56.
2004. View Article : Google Scholar
|
|
26
|
de Dios ST, Bruemmer D, Dilley RJ, Ivey
ME, Jennings GL, Law RE and Little PJ: Inhibitory activity of
clinical thiazolidinedione peroxisome proliferator activating
receptor-gamma ligands toward internal mammary artery, radial
artery, and saphenous vein smooth muscle cell proliferation.
Circulation. 107:2548–2550. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wang TD, Chen WJ, Cheng WC, Lin JW, Chen
MF and Lee YT: Relation of improvement in endothelium-dependent
flow-mediated vasodilation after rosiglitazone to changes in
asymmetric dimethylarginine, endothelin-1, and C-reactive protein
in nondiabetic patients with the metabolic syndrome. Am J Cardiol.
98:1057–1062. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Polikandriotis JA, Mazzella LJ, Rupnow HL
and Hart CM: Peroxisome proliferator-activated receptor gamma
ligands stimulate endothelial nitric oxide production through
distinct peroxisome proliferator-activated receptor gamma-dependent
mechanisms. Arterioscler Thromb Vasc Biol. 25:1810–1816. 2005.
View Article : Google Scholar
|
|
29
|
Chan SH, Wu KL, Kung PS and Chan JY: Oral
intake of rosiglitazone promotes a central antihypertensive effect
via upregulation of peroxisome proliferator-activated
receptor-gamma and alleviation of oxidative stress in rostral
ventrolateral medulla of spontaneously hypertensive rats.
Hypertension. 55:1444–1453. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Walker AB, Chattington PD, Buckingham RE
and Williams G: The thiazolidinedione rosiglitazone (BRL-49653)
lowers blood pressure and protects against impairment of
endothelial function in Zucker fatty rats. Diabetes. 48:1448–1453.
1999. View Article : Google Scholar : PubMed/NCBI
|
